Newsmax TV & Webwww.newsmax.comFREE - In Google Play
Newsmax TV & Webwww.newsmax.comFREE - On the App Store
Drs. Mehmet Oz and Dr. Mike Roizen
Dr. Mehmet Oz is host of the popular TV show “The Dr. Oz Show.” He is a professor in the Department of Surgery at Columbia University and directs the Cardiovascular Institute and Complementary Medicine Program and New York-Presbyterian Hospital.

Dr. Mike Roizen is chief medical officer at the Cleveland Clinic Wellness Institute, an award-winning author, and has been the doctor to eight Nobel Prize winners and more than 100 Fortune 500 CEOs.

Dr. Mehmet Oz,Dr. Mike Roizen

Tags: prostate cancer | IsoPSA blood test | Dr. Oz

Finally a Reliable Prostate Cancer Test

Dr. Mehmet Oz, M.D. and Dr. Mike Roizen, M.D. By Monday, 11 June 2018 04:36 PM EDT Current | Bio | Archive

"The Prostate Monologues" by sportswriter Jack McCallum tried to blow the cover off the all-too-often hushed-up topic of prostate cancer diagnosis, treatment, and life post-treatment.

And while it didn't get turned into a celeb-packed play like Wendy Wasserstein's "The Vagina Monologues," it does shed much-needed light on the subject through one man's experience.

The good news: These days, a new light is being shined on prostate cancer diagnosis — one that might make over 40 percent of prostate biopsies unnecessary.

The IsoPSA blood test, developed by the Cleveland Clinic, is designed to discriminate between high-grade prostate cancer (with a Gleason score of above 7) and low-grade/benign disease (Gleason score of 6 or lower).

Why is this test more accurate than the PSA (prostate specific antigen) test, which has fallen out of favor?

Cleveland Clinic's Dr. Eric Klein, who led the research team that presented the paper "Prospective Validation of the IsoPSA Assay for Detection of High Grade Prostate Cancer" at the recent annual meeting of the American Urological Association, explains: "To be clinically useful, a biomarker must be both tissue-specific and cancer-specific. While PSA is prostate-specific, it is not specific for prostate cancer, leading to diagnostic inaccuracy and too many unneeded biopsies. IsoPSA fulfills both the tissue- and cancer-specificity needed for a useful biomarker."

Clearly this could be a game changer.

So stay tuned for more testing and Food and Drug Administration approvals. Then, Klein says, perhaps the U.S. Preventive Services Task Force recommendation may switch from a "No PSA" test to a "Yes ISO" test.

© 2024 NewsmaxHealth. All rights reserved.

These days, a new light is being shined on prostate cancer diagnosis — one that might make over 40 percent of prostate biopsies unnecessary.
prostate cancer, IsoPSA blood test, Dr. Oz
Monday, 11 June 2018 04:36 PM
Newsmax Media, Inc.

Sign up for Newsmax’s Daily Newsletter

Receive breaking news and original analysis - sent right to your inbox.

(Optional for Local News)
Privacy: We never share your email address.
Join the Newsmax Community
Read and Post Comments
Please review Community Guidelines before posting a comment.
Find Your Condition
Get Newsmax Text Alerts

The information presented on this website is not intended as specific medical advice and is not a substitute for professional medical treatment or diagnosis. Read Newsmax Terms and Conditions of Service.

Newsmax, Moneynews, Newsmax Health, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, and Newsmax World are trademarks of Newsmax Media, Inc.

© Newsmax Media, Inc.
All Rights Reserved
© Newsmax Media, Inc.
All Rights Reserved